Studying Biomarkers in Samples From Younger Patients With Malignant Germ Cell Tumor Progression
NCT ID: NCT01433224
Last Updated: 2016-05-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
90 participants
OBSERVATIONAL
2011-10-31
2016-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research trial studies samples from younger patients with malignant germ cell tumor progression.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
DNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings
NCT01434355
Studying Genes in Samples From Younger Patients With Adrenocortical Tumor
NCT01528956
Gene Expression in Samples From Patients With T-Cell Acute Lymphoblastic Leukemia
NCT01520246
Blood and Tumor Tissue Samples From Young Patients With Acute Myeloid Leukemia
NCT01139333
Biomarkers in Tumor Tissue Samples From Young Patients With Very Low Risk Wilms Tumors
NCT01004783
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Explore inter-tumoral heterogeneity in DNA methylation by tumor histology.
* Determine the genomic methylation pattern in the tumors.
* Correlate methylation pattern with tumor histology and clinical characteristics.
* Carry out exome capture and massively parallel sequencing on selected germ cell tumors (GCTs) and matched normal tissue.
* Perform exome capture and Solexa sequencing on a selected set of GCTs.
* Validate candidate mutations in an independent set of tumors.
* Determine the expression profile of mRNAs, lincRNAs and microRNAs in the tumors using RNA Seq.
OUTLINE: Archived blood and tumor tissue samples are analyzed for genomic methylation pattern, exome capture and sequencing, and candidate mutations by methylation-specific PCR techniques, single nucleotide polymorphism (SNP) arrays, and Solexa sequencing methods. Results are validated by using pyrosequencing assays and primer-extension assays. Methylation pattern is also associated with each patient's tumor histology and clinical data.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DNA methylation analysis
RNA analysis
mutation analysis
nucleic acid sequencing
polymerase chain reaction
polymorphism analysis
laboratory biomarker analysis
medical chart review
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Tumor and blood specimens from patients registered on the Children Oncology Group (COG) Germ Cell Tumor Protocols, and from other study sites for non-COG patients, including Children's Medical Center, Dallas and the Dana-Farber Cancer Institute, Boston
* Patients' clinical data
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
James F. Amatruda, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Simmons Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-AGCT11B2
Identifier Type: OTHER
Identifier Source: secondary_id
AGCT11B2
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2011-03456
Identifier Type: REGISTRY
Identifier Source: secondary_id
AGCT11B2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.